Trials / Recruiting
RecruitingNCT05285839
Dupixent and Narrowband UVB for Atopic Dermatitis
Single Center, Pilot Study to Evaluate the Effectiveness and Safety of Dupilumab in Combination With Narrowband UVB (nUVB) Phototherapy in the Treatment of Moderate-to-Severe Atopic Dermatitis
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Psoriasis Treatment Center of Central New Jersey · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Detailed description
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dupixent | dupilumab 300mg |
Timeline
- Start date
- 2022-04-19
- Primary completion
- 2024-12-01
- Completion
- 2024-12-15
- First posted
- 2022-03-18
- Last updated
- 2024-03-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05285839. Inclusion in this directory is not an endorsement.